Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.
The purpose of this study is to assess the long-term safety and effectiveness of pembrolizumab in patients who took part in a previous pembrolizumab based study. This is called a rollover study.
There are 3 different phases to this study depending on where you were on your initial pembrolizumab study.
Your doctor will be able to advise you on whether this trial is right for you.
- Advanced kidney cancer that cannot be removed by surgery
- Must be enrolled or previously enrolled in a Merck-sponsored pembrolizumab study
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreCross Cancer Institute||Principal InvestigatorDr. Quincy Chu||LocationEdmonton, AB||Trial StatusRecruiting|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal Investigator||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreSunnybrook Research Institute||Principal Investigator||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr. Marcus Butler||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreJewish General Hospital||Principal InvestigatorDr. Wilson Miller||LocationMontreal, QC||Trial StatusRecruiting|